The biopharmaceutical company is a spin-off of the Université Catholique de Louvain and focuses on using allogeneic adult stem cell technology to discover, develop, and commercialize treatments for liver diseases. Promethera Biosciences utilizes a newly discovered and patented progenitor cell type called the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC) to create two products: Cell Signaling Technology for Organ Repair and Regeneration. The company's mission is to provide innovative treatments for liver diseases using allogenic progenitor cells from healthy human livers.